Abstract: Certain aspects of the present disclosure provide techniques for supporting multiple types of random access occasions. A method that may be performed by a user equipment (UE) includes receiving, from a base station (BS), an indication of at least two types of random access occasions (ROs) including a first RO type and a second RO type for communicating in a first coverage area of the BS as part of a random access process for the UE to establish a connection with the BS in the first coverage area. The method further includes transmitting, to the BS, a preamble on an RO of one of the first RO type or the second RO type, wherein a preamble format of the preamble is based on whether the RO is of the first RO type or the second RO type.

Abstract: Disclosed are techniques for positioning. A receiver measures a time of arrival (ToA) of a positioning reference signal (PRS) transmission of a first PRS sequence transmitted by a first transmitter, measures a ToA of a PRS transmission of a second PRS sequence transmitted by a second transmitter, and determines an observed time difference of arrival (OTDOA) as a difference between the ToA of the PRS transmission of the first PRS sequence and the ToA of the PRS transmission of the second PRS sequence, wherein the OTDOA is less than half a maximum differential delay expected between the PRS transmission of the first PRS sequence and the PRS transmission of the second PRS sequence, and wherein a repetition duration of the first PRS sequence and the second PRS sequence is greater than 10 milliseconds (ms) and at least twice the maximum differential delay.

Abstract: Engineered antibody compounds and conjugates thereof, are provided, said antibody compounds and conjugates thereof are useful as agents for cancer immunotherapy. Engineered antibody compounds may include one or more amino acid residue substitutions within the constant regions of the antibody engineered into a parental antibody. Amino acid residue substitutions may include substitution of cysteine or alanine.

Abstract: The present disclosure provides human interleukin 4 receptor alpha antibody glucocorticoid receptor agonist conjugates and methods of using the conjugates for the treatment of inflammatory diseases, such as type 2 inflammatory diseases.

Abstract: The present invention relates to bispecific antibodies that antagonize human PD-1 and agonize human CD137, and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and ionizing radiation.

Abstract: The present disclosure provides human tumor necrosis factor alpha antibody glucocorticoid receptor agonist conjugates and methods of using the conjugates for the treatment of autoimmune and inflammatory diseases.

Abstract: The present disclosure relates to antibodies that specifically bind human IL-4R?, compositions comprising such IL-4R? antibodies, and methods of using such IL-4R? antibodies.

Abstract: The present disclosure relates to antibodies that specifically bind soluble and membrane forms of human TNF?, compositions comprising such TNF? antibodies, and methods of using such TNF? antibodies and compositions.

Abstract: The present disclosure relates to antibodies that specifically bind human IL-4R?, compositions comprising such IL-4R? antibodies, and methods of using such IL-4R? antibodies.

Abstract: The present invention relates to polypeptide molecules that bind to human TIGIT, and to polypeptide molecules that bind to human PD-1 and human TIGIT, and are useful for treating solid tumors, alone and in combination with chemotherapy and/or ionizing radiation.

Abstract: Provided are antibody-drug conjugates (ADCs) that bind to, and kill MET expressing tumor cells, and that are effective in treating MET expressing cancers. Also provided are novel compounds and methods of conjugating MET antibodies to generate such ADCs.

Abstract: The present invention relates to bispecific antibodies that antagonize human PD-1 and agonize human CD137, and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and ionizing radiation.

Abstract: Engineered antibody compounds and conjugates thereof, are provided, said antibody compounds and conjugates thereof are useful as agents for cancer immunotherapy.

Abstract: Provided are antibody-drug conjugates (ADCs) that bind to, and kill MET expressing tumor cells, and that are effective in treating MET expressing cancers. Also provided are novel compounds and methods of conjugating MET antibodies to generate such ADCs.

Abstract: The present invention relates to anti-human PD-1 agonist antibodies, and uses thereof for treating autoimmune disorders such as rheumatoid arthritis or for decreasing rejection of transplanted cells and/or tissues.

Abstract: The present invention relates to anti-human PD-1 agonist antibodies, and uses thereof for treating autoimmune disorders such as rheumatoid arthritis or for decreasing rejection of transplanted cells and/or tissues.

Abstract: The invention relates to cyclic peptide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to cyclic peptide C5a receptor antagonists of formula (Ia) or formula (Ib), or pharmaceutically acceptable salts thereof, wherein R1a, R1b, R2, R3 and R4 areas defined in the description. C5a receptor antagonists are potentially useful in the treatment of a wide range of 1 disorders, including inflammatory disorders and immune disorders.

Abstract: Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.

Abstract: Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.

Abstract: Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.